SCHEMBL7119307

SCHEMBL7119307

C1=CCCC(C2=COC(N3CCN(CCCSc4ccccc4)CC3)=CO2)=C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTR1A P08908 4/20 0.39
DRD2 P14416 4/20 0.39
HTR2A P28223 4/20 0.39
DRD3 P35462 4/20 0.39
DRD1 P21728 3/20 0.39
DRD5 P21918 3/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
ADRA2C P18825 1/20 0.37
HTR7 P34969 1/20 0.37
HRH1 P35367 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
GRM2 Q14416 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125679 0.94 KMT2A (0.46) ALDH1A1KDM4EMEN1KMT2AHTR1A
SCHEMBL7118982 0.89 KCNH2 (0.36) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL7124354 0.89 KCNH2 (0.36) ALDH1A1KDM4EHTR1ADRD2HTR2A
SCHEMBL7123058 0.89 HTR1A (0.34) ALDH1A1KDM4EHTR1ADRD2HTR2A
SCHEMBL7117352 0.88 POLB (0.47) ALDH1A1KDM4EKMT2AHTR1ADRD2
SCHEMBL7128124 0.87 KDM4E (0.34) KDM4EHTR1ADRD2HTR2ADRD3
SCHEMBL7128483 0.87 DRD2 (0.35) HTR1ADRD2HTR2ADRD3DRD1
SCHEMBL7124127 0.86 HTR1A (0.32) ALDH1A1KDM4EHTR1ADRD2HTR2A
SCHEMBL7126603 0.86 DRD2 (0.36) KDM4EHTR1ADRD2HTR2ADRD3
SCHEMBL7124383 0.86 DRD2 (0.34) KDM4EHTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 ALDH1A1 2108/4885KDM4E 2331/4885MEN1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.